EligibleTrials

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting · NCT03907046 · Interventional (participants receive a specific treatment) · Lead sponsor: Yale University

View the official record on ClinicalTrials.gov →
Atrial Fibrillation

Interventions studied

ApixabanAspirin

What this trial is about

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 44 US states.

Showing 60 of 187 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.